FDA Updates Week of April 8: Fasenra Gets New Indication
In a slow week, the FDA has approved Fasenra for children 6 to 11 years of age with eosinophilic asthma, a rare form of asthma.
Fasenra Approved for Children with Severe Asthma
The FDA has approved AstraZeneca’s Fasenra (benralizumab) as an add-on maintenance treatment for children aged 6 to 11 with eosinophilic asthma. Fasenra was first approved in 2017 as an add-on maintenance for the treatment of severe eosinophilic asthma in patients aged 12 and older.
Eosinophilic asthma is a rare type of asthma where white blood cells called eosinophils are elevated, causing inflammation. Fasenra is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and leads to depletion of blood and tissue eosinophils.
This additional indication was supported by evidence from TATE, an open-label, phase 3 trial, as well as trials in adult and adolescent populations. In the TATE study, Fasenra met the primary endpoints, demonstrating pharmacokinetics and pharmacodynamics in the younger patient population that were consistent with those seen in prior trials.
The recommended dose is 30 mg for patients 6 years and older who weigh 35 kg or more. For patients aged 6 to 11 who weigh less than 35 kg, a new 10 mg dose will be available. Fasenra is administered by subcutaneous injection every four weeks for the first three doses, and then every eight weeks.
The list price for Fasenra is $5,511.41 per 30 mg dose. AstraZeneca says for people with employer or individual private insurance, the average out-of-pocket cost is $46 per dose. Some patients may pay as little as $0 for Fasenra and as little as $0 for its injection administration. For people with Medicare Advantage plans, the average out-of-pocket cost is $90 per dose
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
